Get the Stockscreener App
9.71
2.43%
0.23
Aligos Therapeutics Inc stock is traded at $9.71, with a volume of 34,938.
It is up +2.43% in the last 24 hours and up +19.00% over the past month.
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
See More
Previous Close:
$9.48
Open:
$9.51
24h Volume:
34,938
Relative Volume:
0.38
Market Cap:
$30.36M
Revenue:
$7.97M
Net Income/Loss:
$-75.74M
P/E Ratio:
-5.0838
EPS:
-1.91
Net Cash Flow:
$-85.33M
1W Performance:
+3.74%
1M Performance:
+19.00%
6M Performance:
-52.06%
1Y Performance:
-48.91%
1-Day Range:
$9.318
$9.78
1-Week Range:
$8.88
$10.39
52-Week Range:
$6.76
$30.00
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Name
Aligos Therapeutics Inc
Sector
Industry
Phone
(800) 466-6059
Address
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-06-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-23-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-22 | Downgrade | Jefferies | Buy → Hold |
| Sep-09-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Resumed | Piper Sandler | Overweight |
| Nov-10-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Initiated | JP Morgan | Overweight |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Aligos Therapeutics Inc Stock (ALGS) Latest News
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024 - StockTitan
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Drop in Short Interest - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Stock Price Down 5.4% – Here’s What Happened - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Trading Down 5.4%Here's What Happened - MarketBeat
HC Wainwright Reiterates Buy Rating for Aligos Therapeutics (NASDAQ:ALGS) - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Aligos Therapeutics' (ALGS) Buy Rating Reiterated at HC Wainwright - MarketBeat
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184 - The Manila Times
Aligos Therapeutics: ALG-055009 reduces liver fatty deposits in patients with metabolic-dysfunction associated steatohepatitis (MASH) - 2 Minute Medicine
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap UpWhat's Next? - MarketBeat
Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 202 - The Manila Times
Aligos Therapeutics (NASDAQ:ALGS) Trading Down 8.4%Should You Sell? - MarketBeat
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aligos Therapeutics (NASDAQ:ALGS) Sees Strong Trading VolumeHere's What Happened - MarketBeat
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Significant Increase in Short Interest - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Trading 4.9% HigherStill a Buy? - MarketBeat
ALGS stock touches 52-week low at $7.22 amid market challenges By Investing.com - Investing.com South Africa
Aligos Therapeutics (NASDAQ:ALGS) Hits New 1-Year LowWhat's Next? - MarketBeat
ALGS stock touches 52-week low at $7.22 amid market challenges - Investing.com Australia
When the Price of (ALGS) Talks, People Listen - Stock Traders Daily
Aligos TherapeuticsIt's All About Chronic Hepatitis B - RTTNews
Aligos Therapeutics (NASDAQ:ALGS) Shares Down 6.2% - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Trading Down 6.2%Should You Sell? - MarketBeat
Aligos Therapeutics appoints new VP of Business Development By Investing.com - Investing.com Australia
Aligos Therapeutics appoints new VP of Business Development - Investing.com
Aligos Therapeutics Appoints David Perry as Vice President of Business Development - The Manila Times
Aligos Therapeutics to Present at Investor Conferences in October - The Manila Times
(ALGS) Investment Analysis and Advice - Stock Traders Daily
Aligos Therapeutics keeps stock target, overweight rating on promising data By Investing.com - Investing.com Australia
Aligos Therapeutics names new chief medical officer By Investing.com - Investing.com Australia
Aligos Therapeutics keeps stock target, overweight rating on promising data - Investing.com
ALGSAligos Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Aligos Therapeutics names new chief medical officer - Investing.com
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer - StockTitan
Aligos Therapeutics stock hits 52-week low at $8.5 - Investing.com
Aligos Therapeutics stock hits 52-week low at $8.5 By Investing.com - Investing.com Canada
Aligos Therapeutics (NASDAQ:ALGS) Sets New 52-Week Low at $8.28 - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Reaches New 52-Week Low at $8.28 - Defense World
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Down to $14.16 - Defense World
Aligos Therapeutics' (ALGS) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Shares Gap Up to $10.18 - MarketBeat
Aligos Therapeutics (NASDAQ:ALGS) Earns “Buy” Rating from HC Wainwright - Defense World
Market Recap Check: Aligos Therapeutics Inc (ALGS)’s Negative Finish at 10.18, Up/Down -28.11 - The Dwinnex
Aligos Phase II results for ALG-055009 in MASH fail to impress - The Pharma Letter
Aligos shares maintain Buy rating with price target after study - Investing.com
Aligos reports positive data from Phase IIa MASH treatment trial - Clinical Trials Arena
Aligos reports progress in MASH treatment study - Investing.com
Aligos Therapeutics Inc Stock (ALGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):